For Research Use Only. Not for Human or Veterinary Use.
Overview
Retatrutide (development code LY3437943) is a synthetic linear peptide that activates three receptors at once — GIP, GLP-1 and, uniquely for this class, the glucagon receptor (GCGR). Adding glucagon-receptor activity is studied as a way to raise energy expenditure on top of the appetite and glucose effects of the incretin receptors. Like the other agonists in this class it carries a fatty-diacid modification for albumin binding, giving a half-life of about six days.
39-amino-acid peptide (GIP-based) with a C20 fatty-diacid conjugation
Molecular weight
≈ 4840.58 g/mol
Purity (HPLC)
≥ 98%
Appearance
White to off-white lyophilized powder
Retatrutide at a glance
Class
GIP / GLP-1 / glucagon triple agonist
Originator
Eli Lilly and Company
Research status
Under clinical investigation
Study route
Subcutaneous, once weekly
Half-life
≈ 6 days
Key feature
First triple incretin/glucagon agonist in development
🔬Mechanism of Action
Retatrutide is a single peptide engineered to activate three class-B GPCRs — GIPR, GLP-1R and GCGR — all of which couple through Gαs to raise cAMP. The research rationale is complementary: the glucagon-receptor arm is studied for increasing energy expenditure and lipolysis, while the GIP and GLP-1 arms provide insulin secretion and appetite effects and are investigated for offsetting glucagon’s tendency to raise glucose.
Insulin secretion, energy expenditure, lipid metabolism
GCGR
Hepatic glucose handling, energy expenditure, lipolysis, thermogenesis
💊Pharmacology
Parameter
Value
Half-life (t½)
≈ 6 days (~138–155 h)
Time to peak (Tmax)
12–24 h post-dose
Bioavailability (SC)
≈ 75%
Volume of distribution
≈ 0.25 L/kg
Protein binding
≈ 99% (albumin)
Metabolism
Proteolytic degradation (no CYP involvement)
Elimination
Renal (peptide fragments) and fecal
📚Research Evidence
Representative studies and trial programs and what they investigated; specific numerical outcomes are not restated here as claims.
Preclinical model
Research focus
Reference
Diet-induced obese mice
Triple- vs dual-agonism body-weight effects
Coskun T, et al. (2022)
GCGR-knockout mice
Glucagon-receptor-dependent energy metabolism
Knerr PJ, et al. (2023)
Non-human primates
Body-composition and glycemic effects
Sloop KW, et al. (2023)
Clinical program
Phase
Research focus
Reference
Phase 1 / 2 dose-finding
Phase 1–2
Safety and dose–response
Coskun T, et al. (2022)
TRIUMPH-1
Phase 2
Body-weight endpoints in obesity research
Jastreboff AM, et al. (2023), NEJM
TRIUMPH-2 / 3
Phase 3
Ongoing obesity and comorbidity research
Eli Lilly clinical program
Representative reported directions from the literature (qualitative; GLP-1 entries reflect published clinical-trial results, others are reported study directions, not restated as precise product claims):
Reported direction / finding
Context
Reference
Marked body-weight reduction (triple agonism)
Phase 2 obesity
Jastreboff AM et al., NEJM 2023
Triple agonism exceeds dual agonism in preclinical models
DIO mice
Coskun T et al., 2022
Added glucagon-receptor arm raises energy expenditure
rodent metabolism
GCGR knockout studies
For laboratory research use only. Not for human or veterinary use, diagnosis, or therapeutic application. Descriptions refer to published research contexts and are not medical or product claims.
⚗️Dosing & Reconstitution Reference
Reconstitution and handling parameters for laboratory research. Not dosing guidance for human use.
Parameter
Reference value
Research dosing range (literature)
0.25–1.2 mg, once weekly (SC), in study protocols
Reconstitution solvent
Bacteriostatic water (0.9% benzyl alcohol)
Final concentration
≈ 2.5–5 mg/mL
Storage (lyophilized)
−20°C, protected from light
Storage (reconstituted)
2–8°C, up to ~14 days
Do not use
If the solution is cloudy or contains particulates
🛡️Safety Profile
Published safety observations for the compound, provided as research reference only. This material is not for human or veterinary use.
Modest heart-rate increase reported; significance under investigation
Serious (rare)
Pancreatitis and gallbladder-related events at low frequency
Rodent finding
Thyroid C-cell tumors (class effect in rodent studies)
Status
For research use only; not for human or veterinary application
📐Physicochemical Properties
Property
Value
Physical state
White to off-white lyophilized powder
Solubility (water)
Freely soluble (> 50 mg/mL)
logP (octanol/water)
≈ 4.9
Isoelectric point (pI)
≈ 4.9
pH (reconstituted)
7.0–8.0
Stability (lyophilized)
≥ 24 months at −20°C
🏭Synthesis & Manufacturing
Retatrutide is produced by solid-phase peptide synthesis with the C20 fatty-diacid installed on a lysine side chain after selective deprotection — the same overall route as the other long incretin peptides, with coupling efficiency and preparative HPLC as the key steps.
Step
Detail
Strategy
Solid-phase peptide synthesis, Fmoc/tBu chemistry
Resin
Rink amide MBHA resin
Coupling
HATU / HBTU with DIPEA (double couplings for hindered residues)
Fatty-acid conjugation
C20 diacid coupled to a Lys side chain after selective (Mtt) deprotection
Notes: coupling efficiency and complete Fmoc removal are monitored each cycle; hindered or repeated residues (e.g. Arg-Arg) may need double coupling.
Preparative RP-HPLC removes deletion and truncation impurities to reach research-grade purity; salt exchange (lyophilization from dilute HCl) removes residual TFA/acetate.
Critical quality attributes: correct molecular weight and low deletion-peptide content. Long peptide with a fatty-diacid modification; confirm the conjugation.
🔎Analytical Methods
Method
Parameter
Typical result
RP-HPLC (C18, UV 214 nm)
Purity
≥ 98%
HPLC retention
C18, 25–65% B over 25 min
Single main peak
ESI-MS (positive mode)
Identity / mass
[M+H]⁺ ≈ 4841 Da (multiply charged)
MALDI-TOF
Mass confirmation
[M+H]⁺ ≈ 4841 Da (multiply charged)
Amino-acid analysis
Composition
Consistent with the stated sequence
LC-MS (extracted ion)
Deletion-peptide impurities
Within specification
Karl Fischer
Water content
< 6%
LAL assay
Endotoxin
Within specification
Ion chromatography
Residual TFA
< 500 ppm
Representative RP-HPLC purity method:
Column: C18, 5 µm, 250 × 4.6 mm
Mobile phase A: 0.1% TFA in water · Mobile phase B: 0.1% TFA in acetonitrile
Gradient: 25–65% B over 25 min · Flow rate: 1.0 mL/min · Detection: UV 214 nm
Confirmatory LC-MS: ESI positive mode ([M+H]⁺ ≈ 4841 Da (multiply charged)). Long peptide with a fatty-diacid modification; confirm the conjugation.
📈Stability Data
Representative stability behaviour under common storage, handling and formulation conditions.
Condition
Duration
Result
Lyophilized, −20°C, dark
≥ 24 months
No significant degradation (purity > 97%)
Lyophilized, 2–8°C, dark
≥ 12 months
Minimal degradation (purity > 95%)
Lyophilized, 25°C (accelerated)
3 months
< 5% degradation
Reconstituted, 2–8°C, dark
7–14 days
Minor degradation
Reconstituted, 25°C
24–48 h
Use promptly
Light exposure (ICH Q1B)
1.2 M lux·h
Generally light-stable
Freeze–thaw (−20°C ⇄ 25°C)
3 cycles
Acceptable — aliquot to avoid repeats
Keep lyophilized powder cold, dry and light-protected; keep any solution refrigerated and protected from light.
Minimise freeze-thaw cycles; aliquot material used across many sessions.
Key factor: Long peptide with a fatty-diacid modification; confirm the conjugation.
📖Selected References
Coskun T, et al. LY3437943, a novel GIP, GLP-1 and glucagon receptor triagonist. Nature Metabolism / Cell Metabolism, 2022.
Knerr PJ, et al. Glucagon-receptor contribution to the metabolic effects of a triple agonist. Molecular Metabolism, 2023.
Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity. New England Journal of Medicine, 2023.
✅Quality & Supply
HPLC ≥ 98% purity with a Certificate of Analysis per batch
Identity confirmed by LC-MS; endotoxin tested by LAL
Research samples through to bulk, with worldwide delivery